Nexstim Oyj
OMXH:NXTMH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.19
6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Nexstim Oyj
Accrued Liabilities
Nexstim Oyj
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nexstim Oyj
OMXH:NXTMH
|
Accrued Liabilities
€918.3k
|
CAGR 3-Years
28%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
R
|
Revenio Group Oyj
OMXH:REG1V
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Modulight Oyj
OMXH:MODU
|
Accrued Liabilities
€930k
|
CAGR 3-Years
-29%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bioretec Oy
OMXH:BRETEC
|
Accrued Liabilities
€816.9k
|
CAGR 3-Years
41%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
O
|
Optomed Oyj
OMXH:OPTOMED
|
Accrued Liabilities
€2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Biohit Oyj
OMXH:BIOBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nexstim Oyj
Glance View
Nexstim Oyj engages in the provision of medical technology products. The company is headquartered in Helsinki, Etela-Suomen and currently employs 37 full-time employees. The company went IPO on 2014-11-14. The company is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
See Also
What is Nexstim Oyj's Accrued Liabilities?
Accrued Liabilities
918.3k
EUR
Based on the financial report for Jun 30, 2024, Nexstim Oyj's Accrued Liabilities amounts to 918.3k EUR.
What is Nexstim Oyj's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
18%
Over the last year, the Accrued Liabilities growth was 40%. The average annual Accrued Liabilities growth rates for Nexstim Oyj have been 28% over the past three years , 18% over the past five years .
You don't have any saved screeners yet
